Biomedicines (Jun 2023)
Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series
- Daniele Canarutto,
- Chiara Oltolini,
- Federica Barzaghi,
- Valeria Calbi,
- Maddalena Migliavacca,
- Francesca Tucci,
- Vera Gallo,
- Giulia Consiglieri,
- Francesca Ferrua,
- Salvatore Recupero,
- Maria Celia Cervi,
- Hamoud Al-Mousa,
- Anna Pituch-Noworolska,
- Chiara Tassan Din,
- Paolo Scarpellini,
- Paolo Silvani,
- Claudia Fossati,
- Miriam Casiraghi,
- Daniela Maria Cirillo,
- Antonella Castagna,
- Maria Ester Bernardo,
- Alessandro Aiuti,
- Maria Pia Cicalese
Affiliations
- Daniele Canarutto
- Faculty of Medicine and Surgery, Vita-Salute S. Raffaele University, 20132 Milan, Italy
- Chiara Oltolini
- Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Federica Barzaghi
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Valeria Calbi
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Maddalena Migliavacca
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Francesca Tucci
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Vera Gallo
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Giulia Consiglieri
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Francesca Ferrua
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Salvatore Recupero
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Maria Celia Cervi
- Pediatric Infectious Diseases Division, Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo 05508-000, Brazil
- Hamoud Al-Mousa
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia
- Anna Pituch-Noworolska
- Department of Immunology, University Children’s Hospital, 30-663 Krakow, Poland
- Chiara Tassan Din
- Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Paolo Scarpellini
- Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Paolo Silvani
- Department of Anesthesia and Critical Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Claudia Fossati
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Miriam Casiraghi
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Daniela Maria Cirillo
- Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Antonella Castagna
- Faculty of Medicine and Surgery, Vita-Salute S. Raffaele University, 20132 Milan, Italy
- Maria Ester Bernardo
- Faculty of Medicine and Surgery, Vita-Salute S. Raffaele University, 20132 Milan, Italy
- Alessandro Aiuti
- Faculty of Medicine and Surgery, Vita-Salute S. Raffaele University, 20132 Milan, Italy
- Maria Pia Cicalese
- Faculty of Medicine and Surgery, Vita-Salute S. Raffaele University, 20132 Milan, Italy
- DOI
- https://doi.org/10.3390/biomedicines11071809
- Journal volume & issue
-
Vol. 11,
no. 7
p. 1809
Abstract
Vaccination with Bacillus Calmette–Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.
Keywords
